Aethlon Medical Reports Hemopurifier Removes Inflammatory Extracellular Vesicles in Long COVID Study

Aethlon Medical Inc. has announced the publication of preclinical data demonstrating that the GNA affinity resin in its Hemopurifier® device binds to extracellular vesicles (EVs) in plasma samples from Long COVID patients and decreases inflammatory microRNAs. The results, published on November 20, 2025, in the pre-print archive bioRxiv, indicate that the Hemopurifier® removes both large and small EVs, which are elevated in Long COVID patients compared to recovered controls. Additionally, NanoString analyses identified seven EV-associated microRNAs significantly reduced by treatment with the GNA affinity resin. The company stated that these findings support further investigation of the Hemopurifier® in Long COVID. The results from this preclinical study have been submitted for consideration to a peer-reviewed journal and have not yet been presented in a clinical trial context. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aethlon Medical Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA36107) on December 02, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)